328 related articles for article (PubMed ID: 31158085)
1. Pathological Outcomes for Patients Who Failed To Remain Under Active Surveillance for Low-risk Non-muscle-invasive Bladder Cancer: Update and Results from the Bladder Cancer Italian Active Surveillance Project.
Hurle R; Colombo P; Lazzeri M; Lughezzani G; Buffi NM; Saita A; Elefante GM; Morenghi E; Forni G; Cardone P; Lista G; Maffei D; Guazzoni G; Casale P
Eur Urol Oncol; 2018 Oct; 1(5):437-442. PubMed ID: 31158085
[TBL] [Abstract][Full Text] [Related]
2. Active Surveillance for Low Risk Nonmuscle Invasive Bladder Cancer: A Confirmatory and Resource Consumption Study from the BIAS Project.
Hurle R; Lazzeri M; Vanni E; Lughezzani G; Buffi N; Casale P; Saita A; Morenghi E; Forni G; Cardone P; Lista G; Colombo P; Peschechera R; Pasini L; Zandegiacomo S; Benetti A; Maffei D; Vavassori I; Guazzoni G
J Urol; 2018 Feb; 199(2):401-406. PubMed ID: 28847481
[TBL] [Abstract][Full Text] [Related]
3. Active surveillance for low-risk non-muscle-invasive bladder cancer: mid-term results from the Bladder cancer Italian Active Surveillance (BIAS) project.
Hurle R; Pasini L; Lazzeri M; Colombo P; Buffi N; Lughezzani G; Casale P; Morenghi E; Peschechera R; Zandegiacomo S; Benetti A; Saita A; Cardone P; Guazzoni G
BJU Int; 2016 Dec; 118(6):935-939. PubMed ID: 27207387
[TBL] [Abstract][Full Text] [Related]
4. Long-term Follow-up and Factors Associated with Active Surveillance Failure for Patients with Non-muscle-invasive Bladder Cancer: The Bladder Cancer Italian Active Surveillance (BIAS) Experience.
Contieri R; Paciotti M; Lughezzani G; Buffi NM; Frego N; Diana P; Fasulo V; Saita A; Casale P; Lazzeri M; Guazzoni G; Hurle R
Eur Urol Oncol; 2022 Apr; 5(2):251-255. PubMed ID: 34059485
[TBL] [Abstract][Full Text] [Related]
5. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
6. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
[TBL] [Abstract][Full Text] [Related]
7. Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer.
Cantiello F; Russo GI; Vartolomei MD; Farhan ARA; Terracciano D; Musi G; Lucarelli G; Di Stasi SM; Hurle R; Serretta V; Busetto GM; Scafuro C; Perdonà S; Borghesi M; Schiavina R; Cioffi A; De Berardinis E; Almeida GL; Bove P; Lima E; Ucciero G; Matei DV; Crisan N; Verze P; Battaglia M; Guazzoni G; Autorino R; Morgia G; Damiano R; de Cobelli O; Mirone V; Shariat SF; Ferro M
Eur Urol Oncol; 2018 Oct; 1(5):403-410. PubMed ID: 31158079
[TBL] [Abstract][Full Text] [Related]
8. Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA-based urine test, in active surveillance (AS) patients with recurrent non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Italian Active Surveillance (BIAS) project.
Hurle R; Casale P; Saita A; Colombo P; Elefante GM; Lughezzani G; Fasulo V; Paciotti M; Domanico L; Bevilacqua G; Maffei D; Diana P; Frego N; Sandri MT; Maura F; Morenghi E; Buffi NM; Guazzoni G; Lazzeri M
World J Urol; 2020 Sep; 38(9):2215-2220. PubMed ID: 31691083
[TBL] [Abstract][Full Text] [Related]
9. A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years.
Larsson P; Wijkström H; Thorstenson A; Adolfsson J; Norming U; Wiklund P; Onelöv E; Steineck G
Scand J Urol Nephrol; 2003; 37(3):195-201. PubMed ID: 12775276
[TBL] [Abstract][Full Text] [Related]
10. Long-term oncological outcomes of an active surveillance program in recurrent low grade Ta bladder cancer.
Hernández V; Llorente C; de la Peña E; Pérez-Fernández E; Guijarro A; Sola I
Urol Oncol; 2016 Apr; 34(4):165.e19-23. PubMed ID: 26687318
[TBL] [Abstract][Full Text] [Related]
11. The impact of low- versus high-intensity surveillance cystoscopy on surgical care and cancer outcomes in patients with high-risk non-muscle-invasive bladder cancer (NMIBC).
Rezaee ME; Lynch KE; Li Z; MacKenzie TA; Seigne JD; Robertson DJ; Sirovich B; Goodney PP; Schroeck FR
PLoS One; 2020; 15(3):e0230417. PubMed ID: 32203532
[TBL] [Abstract][Full Text] [Related]
12. Long-term Recurrence Rates of Low-risk Non-muscle-invasive Bladder Cancer-How Long Is Cystoscopic Surveillance Necessary?
Ma J; Roumiguie M; Hayashi T; Kohada Y; Zlotta AR; Lévy S; Matsumoto T; Sano T; Black PC
Eur Urol Focus; 2024 Jan; 10(1):189-196. PubMed ID: 37442722
[TBL] [Abstract][Full Text] [Related]
13. The conundrum of recurrent low-grade tumours: to treat or to observe?
Brummelhuis ISG; Witjes JA; Messing EM
Curr Opin Urol; 2018 Nov; 28(6):557-562. PubMed ID: 30239413
[TBL] [Abstract][Full Text] [Related]
14. Impact of bladder neck involvement on progression in patients with primary non-muscle invasive bladder cancer: a prospective validation study.
Kobayashi S; Fujii Y; Koga F; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Masuda H; Kihara K
Urol Oncol; 2014 Jan; 32(1):38.e29-36. PubMed ID: 23702087
[TBL] [Abstract][Full Text] [Related]
15. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.
Dyrskjøt L; Reinert T; Algaba F; Christensen E; Nieboer D; Hermann GG; Mogensen K; Beukers W; Marquez M; Segersten U; Høyer S; Ulhøi BP; Hartmann A; Stöhr R; Wach S; Nawroth R; Schwamborn K; Tulic C; Simic T; Junker K; Harving N; Petersen AC; Jensen JB; Keck B; Grimm MO; Horstmann M; Maurer T; Steyerberg EW; Zwarthoff EC; Real FX; Malats N; Malmström PU; Ørntoft TF
Eur Urol; 2017 Sep; 72(3):461-469. PubMed ID: 28583312
[TBL] [Abstract][Full Text] [Related]
17. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
[TBL] [Abstract][Full Text] [Related]
18. Management of high-risk non-muscle invasive bladder cancer.
Brausi M; Olaru V
Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
[TBL] [Abstract][Full Text] [Related]
19. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.
Zietman AL; Grocela J; Zehr E; Kaufman DS; Young RH; Althausen AF; Heney NM; Shipley WU
Urology; 2001 Sep; 58(3):380-5. PubMed ID: 11549485
[TBL] [Abstract][Full Text] [Related]
20. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder.
Kluth LA; Xylinas E; Crivelli JJ; Passoni N; Comploj E; Pycha A; Chrystal J; Sun M; Karakiewicz PI; Gontero P; Lotan Y; Chun FK; Fisch M; Scherr DS; Shariat SF
J Urol; 2013 Aug; 190(2):480-6. PubMed ID: 23376707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
